Is ABO mismatch another risk factor for allogeneic hematopoietic stem cell transplantation in pediatric thalassemic patients?
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
The ABO incompatibility between donor and recipient is not considered a barrier to successful allogeneic HSCT. Nevertheless, conflicting data still exist about the influence of ABO incompatibility on transplant outcome in pediatric patients with thalassemia. Fifty-one children with beta-thalassemia major who underwent allogeneic HSCT were enrolled this study. Twenty-three of them (45%) received an ABO-incompatible transplant [minor ABO mismatch: six (26%), major ABO mismatch: fourteen (61%), and bidirectional mismatch: three (13%)]. In this study, ABO incompatibility did not significantly impair GVHD, VOD, neutrophil and platelet engraftment, TRM, OS and TFS. Particularly in major and bidirectional ABO-mismatched patients, a delayed erythroid recovery was recorded as compared to the group receiving an ABO-compatible graft (median time, 31 and 38 days vs. 19.5 days; p: 0.02 and p: 0.03). Median time to red cell transfusion independence was significantly longer in major ABO-incompatible patients (median time, 87 days vs. 32 days; p: 0.001). Therefore, whenever feasible, major ABO-mismatched donors should be avoided in HSCT recipients, to prevent delayed erythroid recovery with prolonged RBC transfusion needs and impaired quality of life.
| Errataetall: |
CommentIn: Pediatr Transplant. 2016 Feb;20(1):180-1. - PMID 26581956 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Pediatric transplantation - 19(2015), 6 vom: 17. Sept., Seite 645-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Atay, Didem [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ABO Blood-Group System |
|---|
| Anmerkungen: |
Date Completed 02.05.2016 Date Revised 10.12.2019 published: Print-Electronic CommentIn: Pediatr Transplant. 2016 Feb;20(1):180-1. - PMID 26581956 Citation Status MEDLINE |
|---|
| doi: |
10.1111/petr.12552 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM250708485 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250708485 | ||
| 003 | DE-627 | ||
| 005 | 20231224160412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/petr.12552 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0835.xml |
| 035 | |a (DE-627)NLM250708485 | ||
| 035 | |a (NLM)26156679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Atay, Didem |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is ABO mismatch another risk factor for allogeneic hematopoietic stem cell transplantation in pediatric thalassemic patients? |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2016 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Pediatr Transplant. 2016 Feb;20(1):180-1. - PMID 26581956 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a The ABO incompatibility between donor and recipient is not considered a barrier to successful allogeneic HSCT. Nevertheless, conflicting data still exist about the influence of ABO incompatibility on transplant outcome in pediatric patients with thalassemia. Fifty-one children with beta-thalassemia major who underwent allogeneic HSCT were enrolled this study. Twenty-three of them (45%) received an ABO-incompatible transplant [minor ABO mismatch: six (26%), major ABO mismatch: fourteen (61%), and bidirectional mismatch: three (13%)]. In this study, ABO incompatibility did not significantly impair GVHD, VOD, neutrophil and platelet engraftment, TRM, OS and TFS. Particularly in major and bidirectional ABO-mismatched patients, a delayed erythroid recovery was recorded as compared to the group receiving an ABO-compatible graft (median time, 31 and 38 days vs. 19.5 days; p: 0.02 and p: 0.03). Median time to red cell transfusion independence was significantly longer in major ABO-incompatible patients (median time, 87 days vs. 32 days; p: 0.001). Therefore, whenever feasible, major ABO-mismatched donors should be avoided in HSCT recipients, to prevent delayed erythroid recovery with prolonged RBC transfusion needs and impaired quality of life | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ABO incompatibility | |
| 650 | 4 | |a hematopoietic recovery | |
| 650 | 4 | |a pediatric patients with thalassemia | |
| 650 | 4 | |a transfusion needs | |
| 650 | 7 | |a ABO Blood-Group System |2 NLM | |
| 700 | 1 | |a Erbey, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Akcay, Arzu |e verfasserin |4 aut | |
| 700 | 1 | |a Ozturk, Gulyuz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric transplantation |d 1997 |g 19(2015), 6 vom: 17. Sept., Seite 645-51 |w (DE-627)NLM097406473 |x 1399-3046 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2015 |g number:6 |g day:17 |g month:09 |g pages:645-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/petr.12552 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2015 |e 6 |b 17 |c 09 |h 645-51 | ||